CG
PBYI icon

Cutler Group’s Puma Biotechnology PBYI Stock Holding History

Cutler Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,900
Closed -$18K – 4653
2019
Q1 		$18K Sell
4,900
-4,500
-48% -$137K ﹤0.01% 2114
2018
Q4 		$26K Hold
9,400
– – ﹤0.01% 1930
2018
Q3 		$76K Sell
9,400
-2,500
-21% -$121K 0.01% 1356
2018
Q2 		$134K Sell
11,900
-3,200
-21% -$185K 0.01% 970
2018
Q1 		$238K Buy
15,100
+2,100
+16% +$157K 0.02% 732
2017
Q4 		$308K Sell
13,000
-1,100
-8% -$123K 0.01% 748
2017
Q3 		$634K Sell
14,100
-28,000
-67% -$2.6M 0.02% 536
2017
Q2 		$844K Buy
42,100
+27,800
+194% +$1.56M 0.03% 460
2017
Q1 		$46K Sell
14,300
-9,500
-40% -$347K ﹤0.01% 2496
2016
Q4 		$27K Sell
23,800
-28,500
-54% -$1.23M ﹤0.01% 3161
2016
Q3 		$703K Buy
52,300
+41,200
+371% +$2.08M 0.03% 458
2016
Q2 		$3K Sell
11,100
-13,700
-55% -$428K ﹤0.01% 5408
2016
Q1 		$19K Sell
24,800
-19,600
-44% -$886K ﹤0.01% 3347
2015
Q4 		$110K Buy
+44,400
New +$3.49M 0.01% 1671

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Cutler Group's PBYI Position: Q4 2023 in Review

Cutler Group sold out of Puma Biotechnology (PBYI) in Q4 2023, closing a stake of 200 shares.

Cutler Group first reported a position in PBYI in Q4 2015 and held it in 32 quarters. The position peaked at $4.17M in Q2 2017. 82 funds tracked by Wall St. Rank hold PBYI as of Q4 2023.

  • Cutler Group reported no remaining Puma Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 200 Puma Biotechnology shares in Q4 2023.
  • Cutler Group first reported a position in Puma Biotechnology in Q4 2015 and held it in 32 quarters.
  • Cutler Group's Puma Biotechnology position peaked at $4.17M in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.